Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

5(42%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_1

25%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

3(27.3%)

Phase 2Efficacy & side effects

4(36.4%)

Phase 3Large-scale testing

4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(10)

Completed(1)

Terminated(1)

Detailed Status

Not yet recruiting5

Recruiting4

Active, not recruiting1

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (27.3%)

Phase 24 (36.4%)

Phase 34 (36.4%)

Trials by Status

active_not_recruiting18%

completed18%

not_yet_recruiting542%

recruiting433%

withdrawn18%

Recent Activity

5 active trials

Showing 5 of 12

recruitingphase_3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

NCT07621718

active_not_recruitingphase_2

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT05813626

recruiting

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

NCT07662018

recruitingphase_1

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

NCT07235202

not_yet_recruitingphase_2

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

NCT07554482

View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials

NCT07621718Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Recruiting

NCT05813626Phase 2

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Active Not Recruiting

NCT07662018

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

Recruiting

NCT07235202Phase 1

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

Recruiting

NCT07554482Phase 2

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Not Yet Recruiting

NCT05304936Phase 1

HCW9218 for Advanced Pancreatic Cancer

Completed

NCT07459296Phase 3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Recruiting

NCT07383922Phase 3

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

Not Yet Recruiting

NCT07385079Phase 3

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Not Yet Recruiting

NCT07189793Phase 2

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Not Yet Recruiting

NCT07129772Phase 2

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Not Yet Recruiting

NCT05251038Phase 1

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Withdrawn

All 12 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 12